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Association of coronary atherosclerosis diffusion, Framimgham score
(FRS) and the metabolic syndrome (MS) and its component: anangio-
graphy study
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teur] (1), Rachid Mechmeche (1), Sami Mourali (1), Neziha Kaabachi (1)
(1) Hôpital la Rabta, Explorations Fonctionnelles, Tunis, Tunisie – (2)
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Study to evaluate the relationship between conventional assessment of
the global cardio-vascular risk by means of FRS and the MS and its dif-
ferent component with the coronary atherosclerosis severity.About 425
consecutives patients undergoing angiographic coronary exploration. The
severity of the atherosclerosis diffusion was assessed using a score
assessing the number of vessel-segment with a atherosclerotic plaque
(20% luminal vessel), patients were classed Into 5 groups . We found a
linear correlation between the coronary atherosclerosis diffusion score and
the MS and its component (p=0.04 for all factor) and with the mean of the
FRS. MS and FSR were assessed respectively for the group score0 at:
47.1%,10.9±8.1,group score1 at 44.8%,15±10 , group score 2 at 68.1%,
17±10 , score3 at 73.3%, 18±10 and score 4 at 62%, 28±15 , the difference
was statistically significant, p=0.002 for the MS , and p=0.003 for the FSR
Conclusion:Our study shows that increased FRS are associated with the
severity of the coronary atherosclerosis diffusion likely for the metabolic
syndrome and all its components.
074
Comparison of rosuvastatin and atorvastatin on clopidogrel response
and lipidic and inflammatory parameters after coronary stenting for
acute coronary syndrome 
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Objective: To compare the effect of high doses of rosuvastatin and atorv-
astatin on lipidic, inflammatory parameters and platelet response to clopido-
grel after coronary stenting for Non ST Elevation Acute Coronary Syndrome
(NSTE ACS).
Background: Use of atorvastatin has been reported to decrease signif-
icantly the clopidogrel antiplatelet effect because of cytochrome P450
interaction. Rosuvastatin, a recent developed statin is metabolized via a
different pathway. We investigated whether the coadministration of high
doses of atorvastatin or rosuvastatin for one month in patients with acute
coronary syndromes (ACS) could affect the antiplatelet potency of clopi-
dogrel.
Methods and Results: 138 patients undergoing coronary stenting for
NSTE ACS were prospectively included and randomized to rosuvastatin
20 mg (n=69) or atorvastatin 80 mg (n=69). They received at discharge 75 mg
aspirin and 150 mg clopidogrel. Platelet reactivity indexes VASP and ADP-
induced aggregation were used to assess clopidogrel response. After one
month, clopidogrel response was similar among patients receiving rosuvastatin
and atorvastatin: PRI VASP 44.6.±2.5% vs 46±2.3% respectively, p=0.66 and
ADP-Ag 53.3±1.7% vs 50±2.1% respectively , p=0.23..Inflammatory and
lipid parameters were similar between the two groups and the number of
patients reaching the target LDL cholesterol of less than 2.59 mmol/L was
similar in both groups: 74 % (n=51) with rosuvastatin and 71% (n=49) with
atorvastatin. P=0.85.
Conclusion: our present study suggests that in high risk patients, high dose
of atorvastatin has no negative effect on high maintenance dose of clopidogrel,
while providing same benefit on cholesterol lowering.
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Immediate and long term outcomes of the percutaneous coronary
intervention of the ostia of the major epicardial coronary arteries
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Background: The percutaneous treatment of coronary ostial disease repre-
sent a challenge for the interventional cardiologist and is associated with
higher procedural and long term complication rates. 
Aim of the study: To evaluate the immediate and long term outcomes of
the percutaneous coronary intervention of the major coronary artery ostial
lesion defined as a lesion arising within 3 mm of the vessel origin (LAD, CX,
and RCA)
Methods: A retrospective study on 80 patients, who underwent PCI for
ostial lesions of the left anterior descending, left circumflex, and right coro-
nary arteries over a period from 2001 to 2009 in the cardiology department of
the University Hedi Chaker Hospital of Sfax 
Results: The mean follow up of our patients was 31.17 months (±27,
5 months) .The mean age of our patients was 57.9 years; male predominance
was noted with sex ratio 2 /1. The Myocardial infarction (STEMI) was the
most common reason for admission (37 patients). The remaining patients have
either none elevated ST- Acute Coronary Syndromes (21 patients) nor stable
effort angina (22 patients).
The target lesion was the left anterior descending in 72.5%, the right cor-
onary artery in 21.3% and the circumflex artery in 6.3%.
The mean degree of stenosis was 82.6% (± 14.11) with a mean length of
16.30 mm (± 6, 6 mm). The PCI technic was mainly direct stenting in 54.4%,
a predilatation before stenting in 30.4% and a post dilatation was necessary in
3.8%. PTCA with balloon only has been practiced in 11.4% of cases. A
kissing balloon (LAD_CX) was performed in 18 patients (22.8%).
We used a bare metal stent in 93.1% of cases and drug eluting stent for
6.9% of our population study. 5 PCI were complicated: 2 cases of dissection,
2 effect snow plows (LAD – CX) and one coronary perforation with a proce-
dural complication rate of 6.3%.
42 patients (54.5%) were readmitted after PCI. Target Lesion revascular-
ization (TLR) was 18, 5% and the rate of composite MACE (Death, non fatal
MI, TLR) was 30 %
Conclusion: PCI of ostial narrowings of the major epicardial coronary
arteries was relatively safe. However it was associated with a high incidence
of adverse long term outcomes.
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Calcification in HIV-infected patients, assessed by coronary artery
calcium score (CACS): the VIHCAC study
Romain Chopard [Orateur] 
4, rue Roger Martin du Gard, 25000 Besançon
Background: Human immunodeficiency virus (HIV) – infected patients
may be at higher cardiovascular risk than the non-HIV population. The
VIHCAC study aimed to evaluate the Coronary Artery Calcium Score
(CACS) in comparison with the Framingham Risk Score (FRS) as a predictor
of cardiovascular risk.
Methods: Single-center, prospective cross-sectional study of patients with
HIV infection for more than 5 years and no history of coronary disease. Car-
diovascular risk was estimated by the Framingham Risk Score (FRS), CACS
was calculated using the Agatston method, based on coronary multidetector
computed tomography results. A CACS >10 was defined as abnormal. Inter-
leukin (IL)-6, ultra-sensitive C-reactive protein (us-CRP), glomerular filtration
rate (GFR), and fasting lipids were measured at enrolment. 
Results: 187 patients (mean age 48.7 years, mean HIV disease duration
12.6 years and mean anti-retrovirus exposure 11.1 years) were explored. FRS
was <10% in 113; 10-20% in 66; and >20% in 8. CACS was abnormal in 45
patients (10-100 in 26; 101-300 in 14; and >300 in 5). CACS and FRS corre-
lated poorly (r=0.15, p=0.04). Patients with abnormal CACS were older (53.1
vs. 47.4 years, p=0.0001), had lower GFR (85.7 vs. 98.0 ml/min, p=0.02), and
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higher LDL cholesterol (13.7 vs. 12.8 mg/dL, p=0.07). By contrast, there were
no differences between the two groups as regards duration of HIV infection,
time of exposure to ARVs, (whether considered as a whole or by class), us-
CRP, or IL-6. Of the 45 patients with an abnormal CACS, 41 (91.1%) had
FRS <20% and would not have been eligible for cardiovascular prevention
treatment. These 41 patients represented 22.9% of all patients with FRS <20.
None of the 5 patients with CACS > 300 had been identified as high cardio-
vascular risk patients by FRS. 
Conclusion: In HIV-infected patients, CACS identified presence of coro-
nary atherosclerosis in 22.9% of patients who were deemed to be at low to
intermediate cardiovascular risk based on FRS. 
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Do platelet activity assessment and genotyping help predict outcome
in real world management of patients with ACS?
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Purpose: it has been postulated that outcome of poor metabolizers of clop-
idogrel may be worse in ACS patients. Data about the interest of assessing
platelet reactivity and genotyping in predicting outcome of patients with ACS
taking clopidogrel is still conflicting.
Methods: Prospectively, 120 successive patients (76,7% men, mean
age=60+/–12,2 years) with ACS 45% STEMI) were included. Patients were
excluded if not eligible to clopidogrel therapy or to the platelet activity test.
Patients were managed according to ESC guidelines. Platelet activity was assessed
by a VerifyNow P2Y12 test more than 24h after a 600mg clopidogrel loading
dose. DNA was extracted for genotyping of CYP1A1 and CYP2C19
(*1,*2,*3).MACE (death, infarction, stroke, coronary revascularization) was
assessed at 6 months.
Results: poor platelet inhibition (PRU>230) was noted 54 (46,6%) patients.
CYP1A1 and CYP2C19 low metabolizers (homo and heterozygosis) were respec-
tively 23.1% and 37,5%. MACE at 6 months was noted in 15 (12.5%) patients.
No significant correlation was found between MACE and platelet reactivity test
nor MACE and genotypes CYP1A1 and CYP2C19. combination of platelet
response and resistant genotypes didn’t help to predict MACE.
Conclusion: despite the high rates of poor responders to clopidogel in this
study, assessed by the verify now P2Y12 test and by genotyping (CYP1A1
and CYP2C19), no correlation has been found with MACE at 6 months.
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Introduction: In front of an important request for examination of myo-
cardal scintigraphy following a test of “litigious” effort, we are propose to
complete this work futurology with an aim of answering the question sug-
gested in title, in referent with the results of the myocardial tomoscintigraphy.
Materials and methods: Between January 2008 and May 2010, we investigate
186 consecutive patients presenting of the coronary risk factors addressed for
myocardal tomoscintigraphy in front of a test of litigious effort on the electric
level carried out within the framework of a search for quiet ischemia. Within
the service of nuclear medicine all the patients profited from a test of effort
according to the protocol of Bruce, followed by an examination tomoscintig-
raphy with the MIBI. In the event of a disorder perfusionnel with the myo-
cardic scintiscanning, the patient is taken again for an examination of rest. 
Results: There are 105 women and 81 men whose Middle Age is respec-
tively of 57,4 ± 9,3 years and 59,6 ± 8,2 years. The patients are diabetics in
66% of the cases, 78% are women, hypertensive in 53%. The other risk fac-
tors are also found with variable proportions. The tests of effort carried out
were all maximum. Four 92% of the tests of effort are negative clinically and
“wrongfully positive” electrically. The TSM of these patients is normal in
100% of the cases. In 8% of the cases, the test of effort is positive electrically,
the TSM is normal not detecting any disorder perfusionnel in 73% of the
cases, for the 4 other patients it objectifies disorders perfusionnels; the coron-
arography of these patients is pathological but without significant lesions
except for a patient. This last had in fact finished its test of effort by a non-
constant ventricular tachycardia suggesting a severe ischaemia confirmed with
the coronarography. 
Conclusion: A quite critical reading of under misalignment of the segment
ST during a test of effort diagnoses in particular at the time of the search for
a quiet ischemia, can avoid the recourse to other investigations
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Copeptin has a good negative predictive value in negative troponin I
patients for ruling out an acute myocardial infarction in the emer-
gency department
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Purpose: the aims of this study were to evaluate the novel biomarker
copeptin in combination with troponin I (cTnI), in patients with chest pain
presenting to the emergency department (ED), and to determine whether
copeptin may allow for a rapid rule out of acute myocardial infarction (AMI).
Previous data showed that combined measurement of copeptin and troponin
T(cTnT) improved diagnostic performance for rapid rule out of AMI.
Methods: in 97 patients presenting to the ED with suspicion of AMI, we
performed at admission, a conventional cTnI assay and a novel copeptin
assay.
Results: of 97 patients, 44 (45.4%) had the final diagnosis of AMI,
11(11.3%) of unstable angina and in 42 (43.3%) an acute coronary syndrome
(ACS) could be excluded. Patients with AMI, had copeptin levels higher than
patients with non ACS (20.12 vs 8.97pmol/l p<0.001). At admission, the aera
under curve (AUC) of the receiver-operating characteristic (ROC) curve for
the association cTnI / copeptin was not higher than AUC of cTnI (respectively
0.93 vs 0.89; p=0.177). In 60 patients with negative cTnI (< 0.044 μg/L),
copeptin (< 14 pmol/L) may allow to rule out AMI with sensitivity of 91.0%
and negative predictive value (NPV) of 97.4%.
Conclusions: conversely to what has been demonstrated for cTnT, no sig-
nificant difference in AUC was found when Copeptin/cTnI was compared to
cTnI alone. This can be explained by the limited set of patients and the rela-
tive good result of cTnI AUC. Only combined use of copeptin in negative
cTnI patients might help in ruling out AMI because of its good NPV and
hence improve triage of patients presenting with chest pain in ED.
080
The myocardial infarction of the young subject. Moroccan experience
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Purpose: The aim of this work is to study the specific epidemiological,
clinical, angiographic and evolving myocardial infarction (MI) of the young
subject.
Materials and methods: It is a descriptive retrospective study ruled in the
two services of cardiology of the UHC Mohammed VI de Marrakech from
January 2005 to October 2009. We included the patients admitted for MI and
paired them in two groups: group1 composed of young patients under 45 years
for men and 55 years for women, and group 2 of old patients beyond these age
limits. Patients in both groups were investigated focusing in epidemiological
analysis of cardiovascular risk factors, an ECG, a biological assessment and a
Doppler ultrasound cardiac examination (TTE). The coronarography wasn’t
realized in all cases. 
